Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00

Zevra Therapeutics (NASDAQ:ZVRA - Free Report) had its price target raised by Cantor Fitzgerald from $25.00 to $29.00 in a research note published on Thursday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

A number of other research analysts have also recently issued reports on the company. HC Wainwright assumed coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price objective for the company. Canaccord Genuity Group lifted their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Finally, JMP Securities set a $18.00 price target on Zevra Therapeutics in a report on Wednesday, March 12th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA traded up $0.51 during midday trading on Thursday, reaching $12.53. 1,626,224 shares of the company traded hands, compared to its average volume of 715,282. The firm has a market cap of $685.14 million, a PE ratio of -6.59 and a beta of 1.97. The stock's 50-day simple moving average is $9.06 and its 200-day simple moving average is $8.21. Zevra Therapeutics has a 12 month low of $5.45 and a 12 month high of $12.55. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. The company had revenue of $20.40 million during the quarter, compared to analysts' expectations of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same period last year, the business earned ($0.40) earnings per share. As a group, equities analysts anticipate that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in Zevra Therapeutics by 9.6% in the first quarter. Rhumbline Advisers now owns 74,585 shares of the company's stock worth $559,000 after purchasing an additional 6,532 shares during the period. Strs Ohio acquired a new stake in Zevra Therapeutics in the first quarter worth about $125,000. Woodline Partners LP increased its position in Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock worth $34,571,000 after purchasing an additional 476,032 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after purchasing an additional 1,812 shares during the period. Finally, Retirement Planning Co of New England Inc. increased its position in Zevra Therapeutics by 6.9% in the first quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company's stock worth $4,121,000 after purchasing an additional 35,348 shares during the period. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.